Jaume Capdevila

12.8k total citations · 6 hit papers
128 papers, 8.0k citations indexed

About

Jaume Capdevila is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Jaume Capdevila has authored 128 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 98 papers in Epidemiology and 69 papers in Neurology. Recurrent topics in Jaume Capdevila's work include Neuroendocrine Tumor Research Advances (98 papers), Lung Cancer Research Studies (87 papers) and Neuroblastoma Research and Treatments (67 papers). Jaume Capdevila is often cited by papers focused on Neuroendocrine Tumor Research Advances (98 papers), Lung Cancer Research Studies (87 papers) and Neuroblastoma Research and Treatments (67 papers). Jaume Capdevila collaborates with scholars based in Spain, United States and United Kingdom. Jaume Capdevila's co-authors include Marianne Pavel, Edward M. Wolin, Kjell Öberg, Guido Rindi, Martyn Caplin, James C. Yao, Eric Van Cutsem, Réza Kianmanesh, Timothy J. Hobday and Elisabeth G.E. de Vries and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jaume Capdevila

123 papers receiving 7.9k citations

Hit Papers

Everolimus for Advanced P... 2011 2026 2016 2021 2011 2014 2016 2016 2023 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Everolimus for Advanced Pancreatic Neuroendocrine Tumors
    2011 2.1k citations James C. Yao, Edward M. Wolin et al. New England Journal of Medicine profile →
  2. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
    2014 1.3k citations Martyn Caplin, Marianne Pavel et al. New England Journal of Medicine profile →
  3. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
    2016 911 citations Massimo Falconi, Gregory Kaltsas et al. Neuroendocrinology profile →
  4. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
    2016 738 citations Marianne Pavel, Jaume Capdevila et al. Neuroendocrinology profile →
  5. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery
    2023 149 citations Esmée A. Dijkstra, Per J. Nilsson et al. Annals of Surgery profile →
  6. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
    2024 113 citations Simron Singh, Salvatore Tafuto et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jaume Capdevila 6.6k 6.6k 4.6k 806 629 128 8.0k
Jonathan Strosberg 8.1k 1.2× 8.1k 1.2× 5.8k 1.3× 770 1.0× 586 0.9× 291 9.9k
Marianne Pavel 7.4k 1.1× 7.9k 1.2× 5.7k 1.2× 830 1.0× 494 0.8× 130 9.1k
Catherine Lombard‐Bohas 5.3k 0.8× 5.1k 0.8× 3.6k 0.8× 609 0.8× 666 1.1× 168 6.7k
Nicola Fazio 4.8k 0.7× 4.0k 0.6× 2.7k 0.6× 498 0.6× 944 1.5× 270 6.5k
Diane Reidy‐Lagunes 4.3k 0.7× 3.0k 0.5× 2.1k 0.5× 535 0.7× 1.1k 1.8× 173 5.5k
Ivan Borbath 4.7k 0.7× 3.3k 0.5× 2.0k 0.4× 635 0.8× 1.5k 2.4× 155 6.3k
Pamela L. Kunz 2.9k 0.4× 2.5k 0.4× 1.8k 0.4× 294 0.4× 569 0.9× 101 4.1k
Denis Smith 3.3k 0.5× 2.0k 0.3× 1.4k 0.3× 483 0.6× 535 0.9× 116 4.1k
Massimo Milione 2.3k 0.3× 2.0k 0.3× 1.1k 0.2× 685 0.8× 1.2k 1.9× 185 4.4k
Keith Stuart 2.4k 0.4× 2.1k 0.3× 1.3k 0.3× 585 0.7× 842 1.3× 70 4.6k

Countries citing papers authored by Jaume Capdevila

Since Specialization
Citations

This map shows the geographic impact of Jaume Capdevila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Capdevila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Capdevila more than expected).

Fields of papers citing papers by Jaume Capdevila

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaume Capdevila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Capdevila. The network helps show where Jaume Capdevila may publish in the future.

Co-authorship network of co-authors of Jaume Capdevila

This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Capdevila. A scholar is included among the top collaborators of Jaume Capdevila based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Capdevila. Jaume Capdevila is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Viaplana, Cristina, Joaquı́n Mateo, Francesc Salvà, et al.. (2025). A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Cell Reports Medicine. 6(4). 102032–102032. 3 indexed citations
2.
3.
Hálfdánarson, Þorvarður R., Jaume Capdevila, Daniel M. Halperin, et al.. (2023). Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.. Journal of Clinical Oncology. 41(4_suppl). TPS660–TPS660.
4.
Dijkstra, Esmée A., Per J. Nilsson, Geke A.P. Hospers, et al.. (2023). Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery. Annals of Surgery. 278(4). e766–e772. 149 indexed citations breakdown →
5.
Ramage, John, Elizabeth Friend, Barbara King, et al.. (2022). Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). Journal of Neuroendocrinology. 34(4). e13097–e13097. 4 indexed citations
6.
Capdevila, Jaume, Michel Ducreux, Rocio García‐Carbonero, et al.. (2022). Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 112(12). 1155–1167. 22 indexed citations
7.
Toledo, Rodrigo A., et al.. (2022). Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocrine Reviews. 44(2). 312–322. 47 indexed citations
8.
Mollà, Meritxell, Santiago Albiol, Constantino Fondevila, et al.. (2021). Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. Journal of Clinical Medicine. 10(10). 2131–2131. 15 indexed citations
9.
Vidal, Joana, David Casadevall, Beatríz Bellosillo, et al.. (2021). Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research. 27(10). 2890–2898. 62 indexed citations
10.
Grande, Enrique, Cristina Rodríguez‐Antona, Carlos López, et al.. (2021). Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. The Oncologist. 26(11). 941–949. 16 indexed citations
11.
Grande, Enrique, Àlex Teulé, Teresa Alonso‐Gordoa, et al.. (2020). The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). The Oncologist. 25(9). 745–e1265. 24 indexed citations
12.
Capdevila, Jaume, Oriol Arqués, José Ramón Hernández Mora, et al.. (2019). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. 26(4). 902–909. 28 indexed citations
13.
Grande, Enrique, Carlos López, Ruth Vera, et al.. (2019). Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism. 10. 2388748793–2388748793. 8 indexed citations
14.
Feliú, Jaime, Rocio García‐Carbonero, Jaume Capdevila, et al.. (2019). VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02). Cancer Medicine. 9(3). 1008–1016. 8 indexed citations
15.
González‐Flores, Encarnación, Rafael Serrano del Rosal, Isabel Sevilla, et al.. (2018). SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clinical & Translational Oncology. 21(1). 55–63. 13 indexed citations
16.
Barriuso, Jorge, Ana Custodio, Vicente Alonso, et al.. (2018). Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews. 70. 209–222. 13 indexed citations
17.
Capdevila, Jaume, Federico Rojo, Antonio González-Martı́n, et al.. (2017). Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal. 5(3). 77–85. 4 indexed citations
18.
Yao, James C., Marianne Pavel, Catherine Lombard‐Bohas, et al.. (2016). Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Journal of Clinical Oncology. 34(32). 3906–3913. 192 indexed citations
19.
Caplin, Martyn, Marianne Pavel, Jarosław B. Ćwikła, et al.. (2014). Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. New England Journal of Medicine. 371(3). 224–233. 1286 indexed citations breakdown →
20.
Tabernero, Josep, Luc Dirix, Patrick Schöffski, et al.. (2011). A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(19). 6313–6321. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Strosberg Breakdown of academic impact, for papers by Marianne Pavel Breakdown of academic impact, for papers by Catherine Lombard‐Bohas Breakdown of academic impact, for papers by Nicola Fazio Breakdown of academic impact, for papers by Diane Reidy‐Lagunes Breakdown of academic impact, for papers by Ivan Borbath Breakdown of academic impact, for papers by Pamela L. Kunz Breakdown of academic impact, for papers by Denis Smith Breakdown of academic impact, for papers by Massimo Milione Breakdown of academic impact, for papers by Keith Stuart
Rankless by CCL
2026